Vistagen Therapeutics (NASDAQ:VTGN) Issues Quarterly Earnings Results

Vistagen Therapeutics (NASDAQ:VTGN) issued its quarterly earnings results on Thursday. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.02, Zacks reports. Vistagen Therapeutics had a negative return on equity of 36.35% and a negative net margin of 4,521.71%. The firm had revenue of $230 billion for the quarter, compared to analyst estimates of $0.18 million.

Vistagen Therapeutics Stock Up 4.2 %

VTGN traded up $0.12 during trading on Friday, hitting $2.97. The company’s stock had a trading volume of 265,723 shares, compared to its average volume of 174,465. The firm has a market capitalization of $82.68 million, a P/E ratio of -2.40 and a beta of 0.77. Vistagen Therapeutics has a twelve month low of $2.22 and a twelve month high of $5.74. The stock’s fifty day moving average price is $2.81 and its 200-day moving average price is $2.99.

About Vistagen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.